Real‐world experience of rIX‐FP prophylaxis at dosing intervals of 14 days or more in adult patients with haemophilia B in Italy – Results from IDEAL Part B-Reference-Cited by-同舟云学术

Real‐world experience of rIX‐FP prophylaxis at dosing intervals of 14 days or more in adult patients with haemophilia B in Italy – Results from IDEAL Part B

Published:2024-06-20 Issue:4 Volume:30 Page:1067-1070
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Coppola Antonio¹^ORCID,Peyvandi Flora²,Banov Laura³,Cultrera Dorina⁴,Margaglione Maurizio⁵,Tosetto Alberto⁶,Valdrè Lelia⁷^ORCID,Schiavetti Irene⁸⁹,Loraschi Anna¹⁰,Castaman Giancarlo¹¹^ORCID,

Affiliation:

1. Regional Reference Centre for Inherited Bleeding Disorders University Hospital of Parma Parma Italy

2. Department of Pathophysiology and Transplantation Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi, Haemophilia and Thrombosis Centre, and Università degli Studi di Milano Milan Italy

3. Regional Reference Centre for Haemorrhagic Diseases IRCCS Istituto Giannina Gaslini Genova Italy

4. Haemophilia Regional Reference Centre, Haematology Unit Policlinico “G. Rodolico” ‐ S. Marco Hospital Catania Italy

5. Department of Clinical and Experimental Medicine University of Foggia Foggia Italy

6. Haemostasis and Thrombosis Unit Haematology Department San Bortolo Hospital Vicenza Italy

7. Inherited Bleeding Disorders Unit IRCCS AOUBO Bologna Italy

8. Department of Health Sciences University of Genoa Genova Italy

9. Hippocrates Research Genova Italy

10. CSL Behring Milan Italy

11. Centre for Bleeding Disorders and Coagulation Department of Oncology Careggi University Hospital Florence Italy

Funder

CSL Behring

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.15074

Reference9 articles.

1. Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B

2. IDELVION Coagulation Factor IX [Recombinant] Albumin Fusion Protein (rIX‐FP) Highlights of Prescribing Information. Marburg: CSL Behring GmbH; 2020.https://labeling.cslbehring.com/PI/US/Idelvion/EN/Idelvion‐Prescribing‐Information.pdf

3. IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy

4. Definitions in hemophilia: communication from the SSC of the ISTH

5. WFH Guidelines for the Management of Hemophilia, 3rd edition